+ Filter
Loading...
Custom Services order now ship next day

Anti-IFNA Recombinant Antibody Products

Loading...

Anti-Ifna Products

View More Products

Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag

More Infomation

Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us

For Research Use Only. Not For Clinical Use.


Creative Biolabs is committed to delivering high-quality anti-IFNA antibodies to support researchers in the biomedical field. Understanding the importance of precise antibodies in scientific advancements, we ensure our products meet rigorous quality and reliability standards. Our dedication to excellence enables researchers to access dependable tools, helping them drive meaningful discoveries in their studies.

IFNA: A Crucial Cytokine in Antiviral Defense and Immune Regulation

Interferon-alpha (IFNA) is a crucial cytokine belonging to the type I interferon family, primarily involved in antiviral defense and immune regulation. It is produced by various cell types, particularly plasmacytoid dendritic cells, in response to viral infections. IFNA binds to the interferon-alpha/beta receptor (IFNAR), activating the JAK-STAT signaling pathway, which leads to the transcription of interferon-stimulated genes (ISGs) that enhance the antiviral state of cells. Besides its antiviral properties, IFNA plays a role in modulating innate and adaptive immune responses, influencing T cell activation, natural killer (NK) cell function, and antigen presentation. Due to its immunomodulatory effects, IFNA has been widely studied and utilized in the treatment of viral infections, autoimmune diseases, and certain cancers, such as melanoma and hematological malignancies. However, excessive or prolonged IFNA activity is associated with inflammatory and autoimmune conditions, including systemic lupus erythematosus (SLE). As a critical immune regulator, IFNA remains a key target in therapeutic research, with ongoing studies focused on its modulation for clinical benefits.

Alternative Names

Interferon-α; IFN-α

Background

The IFN-α proteins are produced by leukocytes. They are mainly involved in innate immune response against viral infection. The genes responsible for their synthesis come in 13 subtypes that are called IFNA1, IFNA2, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17, IFNA21. These genes are found together in a cluster on chromosome 9.

Anti-IFNA rAb Products

We are dedicated to offering premium anti-IFNA recombinant antibodies to support and advance research in target-related drug development. Our goal is to facilitate scientific discovery by providing reliable and high-performance products.

Cat. No. Product Name Target Species Host Species Applications
PABL-595 Human Anti-IFNA Recombinant Antibody (clone mAb 01) Human Human WB; IHC; IF; FuncS
MOB-0247MC Mouse Anti-IFNA Recombinant Antibody (clone DE-4) Chicken Mouse WB; ELISA
NEUT-953CQ Rat Anti-Ifna Recombinant Antibody (VMC185) Mouse Rat Neut
NEUT-954CQ Rat Anti-Ifna Recombinant Antibody (clone CBL934) Mouse Rat ELISA; FC; Neut; WB

Customer Reviews

Excellent
L**a
Human Anti-IFNA Recombinant Antibody (clone mAb 01)
(Cat#: PABL-595)
This antibody detects interferon-alpha (IFNA) in biological samples and is suitable for WB, IHC, and IF applications. It offers good specificity and sensitivity, with consistent performance due to recombinant production. Useful for studying immune responses, inflammation, and autoimmune diseases, it supports protein localization and quantification in IFNA-related research.
7/Mar/2023
Excellent
E**ca
Mouse Anti-IFNA Recombinant Antibody (clone DE-4)
(Cat#: MOB-0247MC)
The mouse anti-IFNA antibody is a reliable tool for detecting interferon-alpha in samples, suitable for WB and ELISA. Its recombinant production ensures consistent performance, making it useful for research on immune responses, antiviral activity, and IFNA-related pathways.
12/Apr/2023

rAb Production

With extensive experience in expression vector design, cell line screening, and antibody purification, we provide end-to-end services from gene synthesis to antibody production. Our high-quality solutions enhance research in the biomedical field, ensuring reliability and efficiency throughout the process.

Featured Anti-IFNA Recombinant Antibody Production PlatformsMilligram-scale anti-IFNA recombinant antibody production. (Creative Biolabs Original)
Fig.1 Milligram-scale recombinant antibody production.

Gram-scale anti-IFNA recombinant antibody production. (Creative Biolabs Original)Fig.2 Gram-scale recombinant antibody production.

rAb Modalities

Creative Biolabs is committed to providing diverse recombinant antibody formats tailored to various scientific applications, including basic research and drug discovery. Our antibodies are designed to meet the specific needs of researchers, ensuring high quality and reliability. By offering versatile solutions, we aim to support scientific innovation and contribute to the advancement of biomedical research.

Full Length Anti-IFNA Recombinant Antibody Production and Modalities. (Creative Biolabs Original) Fig.3 Full Length Anti-IFNA Recombinant Antibody Production and Modalities.

Drug Information Targeting IFNA

Table 1. Therapeutic approaches targeting IFNA in clinical development.

Research phase Company Classification Indications Details
Launched - 2021 AstraZeneca
Bristol-Myers Squibb
Biologics Cutaneous lupus erythematosus; Inflammatory myopathy This is a fully human antibody targeting the interferon alpha receptor 1 (IFNAR1).
Launched - 2019 AOP Orphan
PharmaEssentia
Drug Conjugates Chronic myeloid leukemia it was launched for the treatment of adult patients with polycythemia vera.
Launched - 2018 Genova Biotech (Beijing)
Novagen
Biologics Cancer It was launched in 2018 for the treatment of chronic hepatitis B.
Launched - 2017 Biocad Biologics Multiple sclerosis, relapsing-remitting It was first launched in 2017 for the treatment of relapsing-remitting multiple sclerosis (RRMS).
Launched - 2016 Xiamen Amoytop Biotech Drug Conjugates Hepatitis B, chronic; Hepatitis C, chronic The product was launched in 2016 for the treatment of chronic hepatitis C in adult patients.
Launched - 2014 Biogen Drug Conjugates Multiple sclerosis This antibody was approved for the treatment of relapsing-remitting multiple sclerosis.
Launched - 2013 Biocad Drug Conjugates Hepatitis C (HCV) It was launched in 2013 for the treatment of hepatitis C infection.
Launched - 2011 Cadila Healthcare Drug Conjugates Hepatitis B (HBV) It was first launched in 2011 for the treatment of hepatitis B and C.
Launched - 2007 CinnaGen Biologics Multiple sclerosis It is a recombinant glycosylated human interferon beta 1a; produced in CHO cells for the treatment of relapsing forms of multiple sclerosis (MS).

If you would like to learn more about our anti-IFNA recombinant antibody products or have any questions, please feel free to contact us at any time. Our experienced team is committed to providing comprehensive support, offering expert guidance and tailored solutions to meet your specific research needs. We strive to ensure a seamless experience, helping you achieve reliable and impactful results in your scientific work. Your success is our priority, and we are always here to assist you.

Go to compare

Go to compare